12/19
08:00 am
ird
Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy
Medium
Report
Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy
12/12
08:26 am
ird
Opus Genetics, Inc. (NASDAQ: IRD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Medium
Report
Opus Genetics, Inc. (NASDAQ: IRD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
12/3
08:00 am
ird
Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024
Medium
Report
Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024
11/13
09:03 am
ird
Opus Genetics, Inc. (NASDAQ: IRD) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $8.00 price target on the stock.
High
Report
Opus Genetics, Inc. (NASDAQ: IRD) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $8.00 price target on the stock.
11/12
08:00 am
ird
Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update
Low
Report
Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update
11/12
07:59 am
ird
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)